SEARCH

SEARCH BY CITATION

Reference

  • 1
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417429.
  • 2
    Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver 2000; 20: 97103.
  • 3
    McFarlane IG. Definition and classification of autoimmune hepatitis. Semin Liver Dis 2002; 22: 317324.
  • 4
    Papatheodoridis GV, Hamilton M, Rolles K, Burroughs AK. Liver transplantation and inflammatory bowel disease. J Hepatol 1998; 28: 10701076.
  • 5
    Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983; 85: 713717.
  • 6
    Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol 2005; 21: 293299.
  • 7
    Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis 2005; 11: 6272.
  • 8
    Befeler AS, Lissoos TW, Schiano TD et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65: 393396.
  • 9
    Dvorchik I, Subotin M, Demetris AJ et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002; 35: 380384.
  • 10
    Haagsma EB, Van Den Berg AP, Kleibeuker JH, Slooff MJ, Dijkstra G. Inflammatory bowel disease after liver transplantation: The effect of different immunosuppressive regimens. Aliment Pharmacol Ther 2003; 18: 3344.
  • 11
    Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639644.
  • 12
    Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol 1997; 92: 279282.
  • 13
    Verdonk RC, Haagsma E, Van Den Berg AP et al. Inflammatory bowel disease after liver transplantation: A role for cytomegalovirus infection. Scand J Gastroenterol 2005 (in press).
  • 14
    Jungling B, Kindermann I, Moser C et al. Development of ulcerative colitis after heart transplantation during immunosuppressive therapy. Z Gastroenterol 2005; 43: 195199.
  • 15
    Gavaler JS, Delemos B, Belle SH et al. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci 1991; 36: 321328.
  • 16
    Van De Vrie W, De Man RA, Van Buuren HR, Schouten WR, Tilanus HW, Metselaar HJ. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2003; 15: 657663.
  • 17
    Feagan BG. Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol 2003; 98: S6S17.
  • 18
    Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40: 451456.
  • 19
    Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer-Habibi A, Sadatsafavi M. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol 2005; 20: 366370.
  • 20
    D'Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 13231329.
  • 21
    De Saussure P, Soravia C, Morel P, Hadengue A. Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005; 22: 203208.
  • 22
    Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 415423.
  • 23
    Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; 25CD004277.
  • 24
    Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: A long-term experience. Eur J Gastroenterol Hepatol 2005; 17: 7984.
  • 25
    Gonvers JJ, Juillerat P, Mottet C et al. Maintenance of remission in Crohn's disease. Digestion 2005; 71: 4148.
  • 26
    Domenech E, Garcia-Planella E, Bernal I et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 20612065.
  • 27
    Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 2004; 126: 15741581.
  • 28
    Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 15821592.
  • 29
    Baan CC, Van Der Mast BJ, Klepper M et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80: 110117.
  • 30
    Demirkiran A, Kok A, Kwekkeboom J, Metselaar HJ, Tilanus HW, Van Der Laan LJ. Decrease of CD4+CD25+ T cells in peripheral blood after liver transplantation: association with immunosuppression. Transplant Proc 2005; 37: 11941196.
  • 31
    Shibutani S, Inoue F, Aramaki O et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation 2005; 79: 904913.
  • 32
    Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. Regulatory T cells and intestinal homeostasis. Immunol Rev 2005; 204: 184194.
  • 33
    Maul J, Loddenkemper C, Mundt P et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005; 128: 18681878.
  • 34
    Uhlig HH, Powrie F. The role of mucosal T lymphocytes in regulating intestinal inflammation. Springer Semin Immunopathol 2005; 27: 167170.
  • 35
    Sandalova E, Wei CH, Masucci MG, Levitsky V. Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc Natl Acad Sci U S A 2004; 101: 30113016.
  • 36
    Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128: 255266.
  • 37
    Takahashi K, Reynolds M, Ogawa N, Longo DL, Burdick J. Augmentation of T-cell apoptosis by immunosuppressive agents. Clin Transplant 2004; 18: 7275.
  • 38
    Peppelenbosch MP, Van Deventer SJ. T cell apoptosis and inflammatory bowel disease. Gut 2004; 53: 15561558.
  • 39
    Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann N Y Acad Sci 2002; 973: 166180.
  • 40
    Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004; 10: 488491.
  • 41
    Gabe SM, Bjarnason I, Tolou-Ghamari Z et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology 1998; 115: 6774.
  • 42
    De Maar EF, Kleibeuker JH, Boersma-van Ek W, The TH, Van Son WJ. Increased intestinal permeability during cytomegalovirus infection in renal transplant recipients. Transpl Int 1996; 9: 576580.
  • 43
    Koskinen PK, Lemstrom KB, Nieminen MS, Hayry PJ, Lautenschlager IT. Vascular cell adhesion molecule-1 (VCAM-1) is induced during cytomegalovirus infection in vascular structures of heart allografts. Transpl Int 1994; 7(Suppl 1): S363S364.
  • 44
    Orvar K, Murray J, Carmen G, Conklin J. Cytomegalovirus infection associated with onset of inflammatory bowel disease. Dig Dis Sci 1993; 38: 23072310.
  • 45
    Rahbar A, Bostrom L, Lagerstedt U, Magnusson I, Soderberg-Naucler C, Sundqvist VA. Evidence of active cytomegalovirus infection and increased production of IL-6 in tissue specimens obtained from patients with inflammatory bowel diseases. Inflamm Bowel Dis 2003; 9: 154161.
  • 46
    Jain A, Demetris AJ, Kashyap R et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001; 7: 623630.